I am/have/had
I am looking for
Advanced Filters
Found 2 clinical trials
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis
Rationale: Natalizumab is an effective drug in the treatment for relapsing remitting multiple sclerosis (RRMS) and is approved in the treatment regimen of 4-weekly 300mg natalizumab infusions.
extended interval dosing
natalizumab
progressive multifocal leukoencephalopathy
white matter disease
relapsing multiple sclerosis
- 0 views
- 19 Feb, 2024
The Wearing-off Phenomenon of Ocrelizumab in Patients With Multiple Sclerosis
The primary goal of this research is to study the prevalence of the wearing-off effect and possible risk factors for wearing-off symptoms in patients with multiple sclerosis using ocrelizumab with the use of questionnaires. Furthermore, the goal is to study whether patients receiving extended dosing of ocrelizumab experience more wearing-off …
ocrelizumab
multiple sclerosis
- 0 views
- 19 Feb, 2024